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Abstract
Approximately 35 million people worldwide suffer from Alzheimer’s disease (AD). Existing therapeutics, while moderately
effective, are currently unable to stem the widespread rise in AD prevalence. AD is associated with an increase in amyloid
beta (Ab) oligomers and hyperphosphorylated tau, along with cognitive impairment and neurodegeneration. Several
antidepressants have shown promise in improving cognition and alleviating oxidative stress in AD but have failed as long-
term therapeutics. In this study, amitriptyline, an FDA-approved tricyclic antidepressant, was administered orally to aged
and cognitively impaired transgenic AD mice (36TgAD). After amitriptyline treatment, cognitive behavior testing
demonstrated that there was a significant improvement in both long- and short-term memory retention. Amitriptyline
treatment also caused a significant potentiation of non-toxic Ab monomer with a concomitant decrease in cytotoxic dimer
Ab load, compared to vehicle-treated 36TgAD controls. In addition, amitriptyline administration caused a significant
increase in dentate gyrus neurogenesis as well as increases in expression of neurosynaptic marker proteins. Amitriptyline
treatment resulted in increases in hippocampal brain-derived neurotrophic factor protein as well as increased tyrosine
phosphorylation of its cognate receptor (TrkB). These results indicate that amitriptyline has significant beneficial actions in
aged and damaged AD brains and that it shows promise as a tolerable novel therapeutic for the treatment of AD.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
associated with memory and cognitive decline. The public health
impact of AD amplifies as the proportion of elderly people in the
populationincreases.ClassicalbiochemicalhallmarksofADinclude
the accumulation of amyloid beta (Ab) peptide oligomers and
soluble hyperphosphorylated tau aggregates. The generation of
these aggregates has been reported to result in oxidative and
inflammatory damage, leading to metabolic failure and synaptic
dysfunction. Approximately 40% of AD patients develop depressive
symptoms, also known as AD-associated affective disorder, which
itself contributes to cognitive decline [1]. To date, the most effective
AD therapeutics are cholinesterase inhibitors which can partially
improve cognition. However, AD patients suffering from depres-
sion, receiving anticholinesterase therapy, display a significant
decline in cognitive function compared to depressed AD patients
receiving a combination of both anticholinesterases and selective
serotonin reuptake inhibitors (SSRI) [2]. Although combinational
therapy has shown promise, SSRIs and tricyclic antidepressants
(TCAs) have both also been shown to independently reduce the
severity of cognitive decline in non-depressed AD patients [3].
Interestingly, it has also been shown that depressed patients
receiving a low dose of paroxetine (an SSRI) exhibited a 12%
reduction in serum BDNF levels, whereas depressed patients
receiving a low dose of the tricyclic antidepressant amitriptyline
(AMI) showed a 13% increase in serum BDNF levels [4]. Although
TCAs have largely been replaced by SSRIs for the treatment of
depression, TCAs such AMI, are currently prescribed for the
treatment of neuropathic pain at doses well below antidepressant
values, suggesting dose-dependent pluripotent actions of this agent.
Interestingly,itwasrecentlyshownthatAMIpossessesneurotrophic
activity and can bind to and activate the neurotrophin tyrosine
kinase receptor B (TrkB; [5,6]). Neurotrophins are critical for the
maintenance of the peripheral and central nervous systems, and the
beneficial effects of neurotrophic factors on neuronal function and
AD pathophysiology are well known [7,8]. An important consid-
eration for the development of successful AD therapeutics is
whether the agent retains functional efficacy in aged individuals
with advanced pathology and symptomology. To investigate the
potential for a therapeutic that possesses efficacy in aged and
damaged brains we administered a low, chronic dose of AMI to the
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36TgAD mice exhibit age-dependent Ab deposition and tau
pathology in the hippocampus, which is associated with deficits in
spatial learning tasks [9]. We used aged 36TgAD mice (14 months
old), which demonstrated significant AD pathology and cognitive
deficits, to determine the potential beneficial effects of AMI upon
cognitive function and extant AD pathology. We have previously
demonstrated that there are considerable neurophysiological
differences between the 36TgAD mice and their wild-type controls
[10], which may differentially affect drug responses. Therefore, in
this study we have focused mainly on the direct cognitive effects of
AMI treatment on the 36TgAD mouse model as opposed to any
potentialeffectsuponnon-pathophysiologicalanimals.Theultimate
developmental goal of AD therapeutics is effective prophylaxis, but
while early and accurate diagnostic tools are currently unavailable
the ability to demonstrate therapeutic efficacy in a cognitively
impaired disease-related condition is an important therapeutic step
forward.
Methods
Animals and treatment
Animal care and experimental procedures followed NIH
guidelines and were approved by the National Institute on Aging
(NIA) Animal Care and Use Committee under NIA protocol
number 293-LNS-2010. Male 36TgAD mice, 14 months of age,
were maintained on a 12 hr light dark cycle in pathogen free
conditions. Animals received food and water ad libitum. The test
group received 100 mg/g body weight amitriptyline-hydrochloride
per os in their drinking water (Sigma-Aldrich, St. Louis MO) for 4
months (n=15), and the control group received water (n=15).
Two months into the experiment 50 mg/g BrdU was administered
intraperitoneally to both groups daily for 9 days, to examine the
potential effects of AMI on neurogenesis. To ensure that any novel
AMI-generated BrdU-positive cells were stable and mature, two
months were allowed to elapse from initial BrdU injection to the
time of tissue harvest. At the end of the study period, animals were
euthanized with isoflurane inhalation and decapitation. One half
of the brain was carefully dissected on ice, snap frozen and stored
at 280uC for further analyses. The other half of each brain was
fixed in 4% paraformaldehyde for immunohistochemical analyses.
Behavioral testing
The Morris water maze (MWM) was used to assess cognitive
function. The MWM test protocol has been described in detail
previously [11,12]. Briefly, animals were given four trials per day
for seven days to learn the task. On the final day of testing, animals
were given a probe trial in which the platform is removed and the
amount of time spent in each quadrant by the animal is recorded
over a 60 second interval. This probe trial was performed 4 hours,
24 hours and 2 weeks following the final day of training. The
probe trial indicates whether the animal can remember where the
escape platform was located. In addition to the MWM, we also
used the Novel Object Preference (NOP) test to determine
learning and memory ability. The animals were placed in opaque
boxes (for 15 minutes) which contained two identical objects, and
the time spent exploring each object was measured. The following
day, one of the objects was replaced with a new object, and again
the time spent exploring each object was measured (for
15 minutes). Animals that do not exhibit memory impairment
will spend more time exploring the novel object on the second day
of testing. Data was reported as the preference index (PI), i.e. the
total time spent investigating the novel object/total time the
animal spent investigating both objects. Subsequently, we
measured general activity levels using a standard open field
procedure, with 2 zones (I and II), as described previously [11].
The following indices were measured: time spent in specific zone (I
or II), total ambulatory counts, vertical activity counts, and total
vertical activity time. To assess levels of anxiety, the elevated plus
maze was used. The apparatus (San Diego Instruments, San
Diego, CA) consisted of two open arms and two closed arms, that
extended from a common central platform. The apparatus was
elevated to a height of 38 cm above the floor level. Each mouse
was placed in the center square facing an open arm and allowed to
freely explore the apparatus for 10 minutes. The total time spent
exploring the open arms (2 and 4) and the closed arms (arms 1 and
3) was recorded. All behavioral data was collected using Stoelting
Any Maze behavioral tracking software (Wood Dale, IL).
Immunohistochemistry
Hemibrains were fixed in 4% paraformaldehyde (PFA) and
stored in 30% sucrose. Fixed hemibrains were sectioned (40 mm)
using a vibratome, and then processed using standard protocols
[13]. Every eighth section was immunostained using antibodies
directed against Ab (plus antigen retrieval: (5 minutes, 99%
formic acid) or hyperphosphorylated tau (AT8, AT180) using
ABC Vector Elite and diaminobenzidine kits (Vector Laborato-
ries, Burlingame, CA). All antisera (sources and dilutions)
employed are listed in Table S1. Immunohistochemical results
were quantified using two different methods by a researcher
blinded to the experimental conditions. Firstly, Ab immunoreac-
tivity was determined by the immunohistochemistry load
technique [13]. Load values were determined from selected
420 mm6330 mm fields of immunolabeled sections that were
captured and digitized using a video capture system: black and
white CCD camera coupled to an Olympus Optical (Tokyo,
Japan) BX40 upright microscope. Using NIH Image J (v.1.61),
digital grayscale images were converted into binary positive/
negative data using a constant threshold limit. Secondly, the
numbers of Ab deposits and AT8-immunoreactive neurons were
quantified, as described previously [13].
Beta- and gamma-secretase assays
Tissue beta- or gamma-secretase enzymatic activity was
measured in vehicle-treated or AMI-treated mice using specific
fluorometric assay kits (beta-secretase – FP002; gamma secretase –
FP003) obtained from R&D Systems (Minneapolis MN, USA).
Assays were performed using tissue homogenates (final protein
concentration of 1 mg/mL) created using the supplied specific
extraction buffer, according to the manufacturers instructions. The
assays employ secretase-specific substrate peptides conjugated to
the fluorescent reporter molecule EDANS ((5-((2-aminoethyl)ami-
no)naphthalene-1-sulfonic acid) and the molecular quenching
agent DABCYL (4-(dimethylaminoazo)benzene-4-carboxylic ac-
id). Cleavage of the substrate peptides relieves the DABCYL-
mediated fluorescent quenching of the EDANS moiety, therefore
levels of secretase activity (per unit tissue protein) are proportional
to the generated fluorescence, measured using a Molecular
Devices Spectramax 384-Plus plate reader (Molecular Devices
Corporation, Sunnyvale CA).
Western blotting
Hippocampus and cortex tissue was fractionated using the
Qproteome
TM Cell Compartment kit, according to the manufac-
turer’s instructions (Qiagen, Valencia CA). All protein extracts were
quantified using BCA reagent (ThermoScientific, Rockford IL)
before resolution with SDS-PAGE and electrotransfer to PVDF
membranes (Perkin Elmer, Waltham MA). Membranes were
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antibody immune-reactive complexes were identified using alkaline
phosphatase-conjugated secondary antisera (Sigma Aldrich) with
enzyme-linked chemifluorescence (GE Healthcare, Piscataway NJ)
and quantified with a Typhoon 9410 phosphorimager.
Cell culture and treatment
Dissociated hippocampal and cortical neuron cultures were seeded
in poly-D-lysine-coated plates and grown in Neurobasal medium
(Invitrogen, Carlsbad CA), and supplemented with B27 (Invitrogen)
and 0.5 mM glutamine. Following 7, and in some cases 21, days of
maturation, cells were treated with AMI for 3 days, and control cells
received phosphate-buffered saline (PBS) vehicle. Cells were then
scraped into an NP40-based lysis buffer (250 mM NaCl, 5 mM
HEPES, 10% Glycerol, 0.5% NP40, 0.5% Triton-X 100, 2 mM
EDTA, protease inhibitors), agitated for 40 minutes at 4uC, and then
centrifuged at 14000 rpm/4uC for 15 minutes. Supernatant protein
lysates were normalized (1 mg/ml) before western blotting procedures
(see above). For acute AMI-stimulation experiments, hippocampal/
cortical cells were incubated for 40 minutes in artificial cerebrospinal
fluid before AMI exposure (for the time period indicated). After
stimulation, cell monolayers were lysed in the NP40-based lysis buffer
and prepared for western blotting. Hippocampal and cortical cells for
confocal microscopy were seeded in eight well chamber slides
(ThermoFisher, Rochester NY). Ten days following seeding, cells
were treated with AMI for 3 days. For immunostaining, neurobasal
growth media was aspirated and monolayers were washed with PBS
and fixed in ice-cold 4% PFA for 20 minutes. Cell monolayers were
washed twice with PBS, and then incubated in permeabilization
buffer (Tris-buffered saline, 10% goat serum, 0.1% Triton-X 100,
30 minutes). After permeabilization, monolayers were incubated with
anti-MAP2 sera. Cells were then incubated with a 1:2000 dilution of
a rhodamine-conjugated anti-mouse antibody for 1 hour at room
temperature. Monolayers were washed with PBS between primary
and secondary antibody incubations,and also before visualization. For
neuronal progenitor cell preparation [14], C57/BL6 embryonic day
14 (E14) pups were employed. Progenitor cells were seeded into poly-
L-lysine-coated 6 well plates. Cells were then maintained in DMEM
supplemented with B27 supplement (Invitrogen), 25 ng/mL fibroblast
growth factor and 25 ng/mL epidermal growth factor. Cells were
treated with AMI (10–20 nM), 10 ng/mL brain-derived neurotrophic
factor (BDNF) or PBS (vehicle control) for 2 weeks. Cells were then
lysed (8% SDS, 125 mM Tris-HCl, pH 7.4) sonicated, and
centrifuged (14000 rpm, 10 minutes), before protein concentration
determination and normalization (1 mg/mL). All experiments were
carried out in triplicate.
Immunoprecipitation
Primary cortical and hippocampal cells were treated with AMI for
the specified time period/dose and subsequently lysed in an ice-cold
RIPA buffer. Lysates were agitated for 20 minutes at 4uCb e f o r e
centrifugal clarification (14000 rpm/10 minutes/4uC). Normalized
supernatant protein lysates were pre-cleared using protein A/G pre-
conjugated agarose beads (EMD Chemicals, Gibbstown NJ). PY20
(anti-phosphotyrosine) pre-conjugated sera (Santa Cruz Biotechnol-
ogy, Santa Cruz CA) was then added to pre-cleared supernatants with
agitation at 4uC. Immunoprecipitates were collected via centrifuga-
tion, washed in RIPA buffer and proteins were eluted in 30 mL
Laemmli (8% SDS) buffer. Samples were then processed for western
blotting. For tissue immunoprecipitations, plasma membrane frac-
tions obtained with Qproteome
TM fractionation were normalized,
pre-cleared, incubated with anti-PY20 and processed further as
described previously [15].
RNA extraction and microarray analysis
RNA isolation, subsequent cDNA generation, labeling and
hybridization to Illumina Sentrix Mouse Ref-8 Expression Bead-
Chips (Illumina, San Diego, CA) was carried out as previously
described [15]. Arrays were scanned using an Illumina BeadStation
Genetic Analysis Systems scanner and the image data extracted
using the Illumina BeadStudio v.3.0. We have deposited the raw
transcriptomic data in this manuscript at GEO/ArrayExpress
under accession number GSE26836, we can confirm all details are
MIAME compliant.
Bioinformatic analysis
Microarray data were analyzed using DIANE 6.0. Raw
microarray data were subjected to filtering and z normalization
and tested for significant changes, as described previously [15].
Sample quality (in triplicate) was analyzed by principal component
analysis and then genes were filtered with a z-ratio cut-off at 61.5
with an associated false discovery rate ,0.3 with a statistical
probability (p) value#0.05. These data were further analyzed using
ANOVA with significance set at p#0.05. After identifying
individualgenesthatweresignificantlyregulatedbyAMItreatment,
genesets were analyzed using: signaling pathway analysis (pathways
defined by the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (http://www.genome.jp/kegg/); MSigDB-Parametric
Geneset Enrichment analysis (PAGE: (http://www.broadinstitute.
org/gsea/msigdb/index.jsp) and scientific abstract latent semantic
indexing using GeneIndexer (https://computablegenomix.com/
geneindexer). GeneIndexer correlates the strength of association
between specific factors (e.g. genes or proteins) in a dataset with a
user-defined interrogation term [12]. GeneIndexer employs a 2010
murine or human database of over 1610
6 scientific abstracts to
perform text-gene/protein correlation analysis. LSI facilitates the
specific textual interrogation ofan input dataset with a specific term,
i.e. Alzheimer’s disease, to ascertain which of the input dataset genes
are explicitly associated with the interrogation term. Using LSI
algorithms, not only is the direct interrogation term used to analyze
the input dataset but also closely correlated additional terms,
implicitly associated with the user-defined interrogation term, are
also employed in the search patterns. A latent semantic indexing
correlation score indicates the strength of association of the
interrogation term and the specific genes in the dataset. A highly
relevant gene-term correlation yields a large number of explicitly/
implicitly associated genes with high LSI correlation scores.
Therefore, a strong correlation between the genes in a dataset
and a specific user-defined interrogation term yields a large number
of correlated genes with high LSI correlation scores.
For the functional clustering of genes into KEGG pathways,
using WebGestalt [10], we used a cutoff of $2 genes per KEGG
pathway at a p value of #0.05. To assess the degree of KEGG
pathways population, a ‘hybrid’ scoring system was used: hybrid
score=gene-set enrichment (R)62log10 of the probability (p) of
that enrichment. Similar criteria (n$2 genes per PAGE collection,
p#0.05) wereused for the clustering of genes into the MSigDB gene
collections. The resultant PAGE z-score is calculated from the
individual z-ratios of each experimentally identified gene that
populates the specific collection. GeneIndexer genes were only
consideredtoimplicitlycorrelatewiththeuser-definedinterrogation
term that possessed a latent semantic indexing correlation of $0.1.
Statistical Analysis
For statistical analysis, a non-paired two-way Student’s t-test
was applied using GraphPad Prism v. 5.0. Statistical significance
was considered from p#0.001 to p#0.05.
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AMI alters Ab and tau deposition
36TgADmicereceivedAMI-hydrochloridefor4monthsintheir
drinking water. Compared to vehicle-treated mice, AMI treatment
significantly increased Ab plaque load in the global hippocampus
(Figure 1A:p=0.0048), subiculum (Figure 1B):p=0.045, CA1
(Figure 1C:p=0.001) and amygdala (Figure 1D:p=0.036). AMI-
treatment also significantly increased (p=0.00098) tau paired
helical filaments (PHFs) (Figure 1F), detected using the specific
AT8 antisera. We assessed b-o rc-secretase activity in AMI or
vehicle-treated animal hippocampus or cortex and detected no
significant activity difference in either group (Figure S1). As Ab
plaques, as entities in themselves, may have a variable association
with cognitive decline [16], we compared the effect of AMI upon
the Ab dimer to monomer ratio. Using hippocampal subcellular
compartmentalization, we found that the AMI-increased Ab
present in the cytoplasmic fraction was of the non-toxic monomeric
form, whereas the vehicle-treated group contained almost no
monomer(Figure1G).Both dimericandmonomericAb werenoted
in the vehicle- and AMI-treated mice insoluble hippocampal
compartment. AMI treatment caused a significant increase in
monomeric Ab and a decrease in dimeric Ab (Figure 1G:p=0.03).
In contrast to hippocampal Ab expression, only dimeric Ab was
found in the cytoplasmic fraction of cortical extracts (Figure 1H).
AMI-treatment significantly reduced cortical cytoplasmic Ab dimer
levels (Figure 1H:p=0.046). AMI also significantly increased
insoluble cortical monomeric Ab (Figure 1H:p=0.01). A trend for
AMI-mediateddecreaseininsolublecorticaldimericAb(Figure1H)
was also observed. We also investigated AMI-mediated changes in
the microtubule protein tau. PHFs are large complexes of
phosphorylated tau [17]. We used standardized ultracentrifugation
protocols to investigate AMI effects upon hippocampal tau
disposition. Ultracentrifugal supernatants, containing the soluble
fraction, were exposed to a ‘total’ tau antibody demonstrating that
AMI-treated extracts contained significantly less soluble tau protein
(Figure 1I). Using the AT180 anti-tau sera, that recognizes the
hyperphosphorylated tau PHF parts of neurofibrillary tangles, we
found that AMI-treatment reduced this immunoreactivity in the
hippocampus of the 36TgAD mice (Figure 1J). This suggests that
Figure 1. AMI affects Ab and tau in aged 36TgAD mice. Vehicle (veh)- and AMI-treated Ab expression in 36TgAD hippocampus (A), frontal
cortex subiculum (B), CA1 region (C), and amygdala (D). (E) AMI/veh effects on Ab load in the frontal cortex. (F) AMI/veh effects on hippocampal PHF
load. Histograms depict relative quantification of associated panels (A–F). AMI effects on hippocampal (G) or cortical (H) Ab disposition. (I) AMI/veh
effects upon total soluble hippocampal tau levels. (J) AMI/veh effects upon soluble phosphorylated PHF tau. For this and subsequent analyses, values
in histograms represent mean 6 SEM (n=6), *p,0.05, ** p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0021660.g001
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with large insoluble inert tangles and are less toxic to the cell than
more soluble forms of this complex [18].
AMI affects expression of multiple neurosynaptic
signaling proteins
AMI treatment resulted in significant increases in hippocampal
tissue expression of both pre-synaptic (synaptophysin, synapsin I:
Figure 2A–B) and post-synaptic (post-synaptic density protein 95
(PSD95), spinophilin: Figure 2C–D) proteins. Acute AMI treatment
of isolated murine hippocampal neurons (7 days in culture) also
resulted in increased PSD95 and synapsin I (Figure 2E–F)
expression. In addition we also demonstrated that similar AMI-
mediated effects upon synapsin I and PSD95 expression occurred in
primary hippocampal cells after an extended period (21 days) of in
vitro culture (Figure S2A, B). In murine cortical tissues, minimal
changes or small decreases in synaptophysin, synapsin I or PSD-95
(Figure 2G–I) were noted with AMI-treatment, and a modest
increase was observed for spinophilin (Figure 2J). Primary murine
cortical neurons (7 days in culture) were also responsive to in vitro
AMI treatment through an increase in synaptic marker proteins
(Figure 2K, L). Similar effects of AMI upon cortical PDS95 and
synapsin I expression were observed in extended in vitro culture (21
days) primary cortical cells (Figure S2C, D). AMI also potentiated
hippocampal tissue BDNF, but not NGF levels (Figure 2M,N). AMI
significantly increased (p=0.0036) the phosphotyrosine content of
immunoprecipitated hippocampal TrkB (Figure 2O). No changes in
cortical/hippocampal TrkA or B receptor levels were seen with
AMI treatment (data not shown). AMI also increased hippocampal
Akt-1 activity (phospho-Ser473:Figure 2P). AMI did not alter
cortical BDNF or NGF expression (Figure 2Q–R). AMI potentiated
cortical TrkB phosphotyrosine content (Figure 2S), without
elevation of Akt-1 activity (Figure 2T). We assessed the in vitro
effects of AMI upon these neuroprotective mechanisms with
primary murine hippocampal and cortical neurons. Acute AMI
stimulation increased TrkB phosphotyrosine content (Figure 2U,V)
Figure 2. AMI alteration of various synaptic factors. AMI and vehicle (veh)-mediated effects upon hippocampal expression of (A)
synaptophysin, (B) synapsin I, (C) PSD95 and (D) spinophilin. AMI effects on PSD95 (E) and synapsin I (F) expression in primary hippocampal cells. AMI/
veh-mediated effects upon cortical expression of (G) synaptophysin, (H) synapsin I, (I) PSD95 and (J) spinophilin. AMI effects on PSD95 (K) and
synapsin I (L) expression in primary cortical cells. AMI modulation of hippocampal BDNF (M), NGF (M) levels, TrkB tyrosine phosphorylation (O) and
Akt-serine (Ser)-473 phosphorylation (P). AMI effects upon TrkB tyrosine phosphorylation in primary hippocampal (U) or cortical neurons (V). AMI
regulation of cortical BDNF (Q) or NGF (R) levels, TrkB tyrosine phosphorylation (S) and Akt-1 Ser-473 phosphorylation (T). AMI effects upon Akt-1 Ser-
473 phosphorylation in primary hippocampal (W) or cortical neurons (X). Western band intensities were quantified as actin-normalized arbitrary
absorbance units (AU).
doi:10.1371/journal.pone.0021660.g002
Amitriptyline Exerts Pro-Cognitive Effects
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21660and activated Akt-1 (Figure 2W,X) in hippocampal and cortical
neurons (7 days in culture). These acute effects of AMI stimulation
upon TrkB and Akt-1 were also repeated in primary hippocampal
and cortical neurons pre-cultured for an extended period as well (21
days: Figure S2 E, F-hippocampus; G, H-cortex). These multiple
neurosynaptic effects of AMI indicate an ability to regulate TrkB
receptors and stimulate pro-survival/neurotrophic pathways in vivo
andinvitro.Therefore,wesubsequentlyassessed whetherAMIcould
exert pro-cognitive beneficial effects in these aged AD mice.
AMI significantly improves spatial learning and memory
in aged and cognitively-impaired 36TgAD mice
The effects of AMI treatment upon the cognitive capacity of the
aged and cognitively-impaired 36TgAD was assessed using the
standard Morris Water Maze (MWM: Figure 3A). As our treatment is
specifically targeted to the amelioration of the specific pathological
Alzheimer’s cognitive condition, we focused our study on the drug
effects in symptomatic transgenic 36TgAD mice. In addition, as wild-
type and 36TgAD mice demonstrate significant neurosynaptic
differences [10], comparison of drug responses between the two may
lead to erroneous conclusions regarding drug mechanisms and efficacy.
In Figures 3B and 3C it is clear that the control (vehicle-treated)
36TgAD mice are cognitively impaired as they did not demonstrate a
typical reduction in escape latency time across the four platform trials
on the first trial day (Figure 3B), or any reduction in time to find the
escape platform on subsequent days of MWM training (Figure 3C).
AMI-treated mice demonstrated a progressive MWM escape latency
reduction over successive trials in their first day of training. The AMI-
treated 36TgAD mice demonstrated a significantly reduced escape
latencybythethirdtrialontheirfirstdayofMWMtraining(Figure3B).
Upon repetition of the MWM training over successive days it was clear
that AMI treatment greatly enhanced the ability of the 36TgAD mice
to learn the maze task (Figure 3C). Even on the first complete day of
MWM testing, AMI-treated mice demonstrated a significantly reduced
basal escape latency (averaged across the four trials per day per mouse),
Figure 3. AMI improves learning and memory in 36TgAD mice. (A) Morris water maze (MWM) used. (B) AMI/veh effects upon day 1 platform
escape latency. (C) AMI/veh effects upon MWM platform acquisition measured by escape latency in seconds. Grey panel indicates 3 time points after
the seventh day of MWM testing for the probe trial, as described in Methods. (D) AMI effects upon time spent in MWM platform quadrant during 3
probe trial time periods after MWM acquisition. (E) AMI effects upon number of platform traverses during the 3 probe trial time periods after MWM
acquisition. (F) Novel object preference (NOP) protocol. (G) AMI/veh effects upon 36TgAD NOP index. (H) Open field test employed. AMI/veh or
effects on open field performance: distance traveled (I); time spent in specific zone (J); total ambulatory activity counts (K); vertical activity counts (L)
and total vertical activity time (M). (N) Elevated plus maze employed (arms 1 and 3=dark). (O) AMI effects upon total time spent in open arms 2 and 4.
doi:10.1371/journal.pone.0021660.g003
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On each successive trial day the AMI-treated mice demonstrated a
progressive reduction in the time to reach the escape platform.
Removal of the hidden platform, creating a classical MWM probe trial,
demonstrated that AMI-treated mice effectively retained the memory
of the platform position after 4 hrs, 24 hrs and even 2 wks post
platform testing (Figure 3C, shaded area). The probe-trial search
pattern, indicated by time spent in the relevant quadrant zone during
the probe trial, of vehicle-treated 36TgAD mice was random (#25%),
whereas that ofAMI-treated 36TgAD mice was more specific ($50%:
Figure 3D). The number of platform zone entries of AMI-treated
36TgAD mice during the probe trialwassignificantlygreaterthanthat
for the vehicle-treated group at each time point (Figure 3E). We also
employed an additional test of memory-related cognitive function, i.e.
the novel object preference (NOP) test (Figure 3F). AMI-treated
animals demonstrated a significantly greater preference for interaction
with the novel object than the 36TgAD vehicle-treated mice
(Figure 3G:p=0.00066). Thus, our findings from the NOP test
confirmed our findings from the MWM, in that AMI was able to
effectively rescue the cognitive impairment of the aged 36TgAD mice.
It is however known that the MWM test can cause increased anxiety
in mice, particularly the 36TgAD strain [11]. Improved MWM
performance therefore may be due to an anxiolytic effect that can be
induced by TCAs such as AMI. To investigate whether the AMI-
enhanced MWM performance was anxiolytically-based, we performed
open field and elevated plus maze testing. No difference in any of the
open field (schematically represented in Figure 3H) measurement
indices between AMI- or vehicle-treated 36TgAD mice were noted
(Figure 3I–M). Any significant anxiolytic action of AMI would likely
affect one or more of these parameters. Additionally, no significant
anxiolytic effects in AMI-treated 36TgAD animals was observed in the
elevated plus maze (schematically represented in Figure 3N) test
(Figure 3O), again suggesting that pro-cognitive AMI actions may lie
outside typical antidepressant/mood stabilization effects, and may be
more associated with neurotrophic functions.
AMI activates genomic transcription patterns related to
neurotrophic rather than antidepressant actions
To assess, in an unbiased manner, the potential molecular
mechanisms mediating the pro-cognitive actions of AMI we
performed transcriptional analysis of treated versus control hippo-
campal and cortical tissues. AMI-treatment, compared to vehicle
control, significantly altered transcription of 223 (Table S2) and 149
(TableS3)genesinthehippocampusandcortexrespectively.Asmall
overlap of significantly regulated genes between the two tissues was
noted (Figure 4A). Of the common transcripts, 3 were upregulated,
annexin A3 (Anxa3), solute carrier family 30 (zinc transporter)
member5 (Slc30a5) and N-myc downstreamregulated gene4 (Ndrg4:
Figure 4B). The 4 common downregulated transcripts were:
ribosomal protein S15a (Rps15a), seizure related 6 homolog like 2
(Sez6l2), centrosomal protein 110 kDa (Cep110) and transmembrane
channel-like gene family 7 (Tmc7). Only 2 common transcripts were
differentially regulated, ATPase, H
+ transporting, lysosomal V0
subunit A1 (Atp6v0a1) and bromodomain containing 2 (Brd2)w e r e
downregulated inthe cortex and upregulated inthe hippocampus by
AMI treatment (Figure 4B). To assess the AMI transcriptomic
response patterns at an integrated, higher functional level, we
subjected the significantly regulated genesets to unbiased computa-
tional signaling pathway analysis. AMI-regulated genesets were
subjected to pathway enrichment analysis using the KEGG (Kyoto
Encyclopedia of Genes and Genomes) database. KEGG database
interrogation with the AMI-regulated hippocampal geneset resulted
inthesignificant (p#0.05)population ofsignaling pathwayslinked to
cell signaling and neurosynaptic activity (neurotrophin signaling, ErbB
signaling, Toll-like receptor signaling, MAPK signaling), protein metabolic
pathways (proteasome, lysosome, ribosome) and cellular architecture
pathways (focal adhesion, ECM-receptor interaction, cell adhesion molecules)
(Figure 4C). KEGG database interrogation with the AMI-regulated
cortical geneset resulted in the population of a similar cluster of
signaling pathways compared to the hippocampus, however fewer
cell signaling pathways were populated (6-hippocampus, 2-cortex:
Figure 4D). The Molecular Signatures Database (MSigDB) contains
interrogatable, curated gene collections that represent complex
physiological experimental paradigms, as opposed to the more rigid
signaling pathways of the KEGG database. Therefore, interrogation
of the MSigDB may also assist analogy of the AMI effects with
previously identified physiological paradigms. The significantly
populated (p#0.05) MSigDB geneset collections from the hippo-
campal (Figure 4E) or cortical (Figure 4F) AMI-regulated transcripts
demonstrated a strong pro-cognitive therapeutic profile. In the
hippocampus, AMI treatment resulted in the upregulation of a
collection of genes shown to be downregulated in AD (ALZHEI-
MERS_DISEASE_DN), with a concomitant downregulation of genes
typically upregulated in AD pathology (ALZHEIMERS_DISEA-
SE_UP). In both of these gene collections, we identified the
significant AMI-regulation of over 60% of the total number of
base-set genes in each collection (Figure 4E). Interestingly, AMI was
unable to reverse the presentation of genes related to a depressive
phenotype (ASTON_DEPRESSION_DN). An effective reversal of
AD-related pathology genes in cortical tissues was also seen in AMI-
regulated MSigDB collections (Figure 4F). We also noted a strong
AMI-mediated upregulation of neural stem cell activity (STEM_-
CELL_UP, STEM_CELL_COMMON_UP), changes in cell cycle
(CELL_CYCLE_ARREST, CELL_CYCLE) and reversal of age-related
genetic changes (AGEING_BRAIN_DN).
A potential mechanism by which AMI could enhance cognitive
function, in the presence of increased classical AD pathology,
could be a neuronal re-population of CNS regions via adult
neurogenesis. New neurons could support or re-populate disrupted
signaling networks to achieve cognitive enhancement. As we had
seen a strong pro-neurotrophic effect in the protein expression,
enhanced cognitive function and stem-cell related activity in the
geneset analysis (with negligible antidepressant-like activity), we
next assessed whether AMI-controlled genesets were more related
to neurogenic actions than antidepressant activity. Using a latent
semantic indexing (LSI) process (Computable Genomix, GeneIn-
dexer), the correlation to curated scientific abstracts of input
dataset genes with a user-defined interrogation term can be
assessed. Using GeneIndexer interrogation we noted that consid-
erably more AMI-regulated genes correlated with the ‘neurogenesis’
term, compared to the ‘antidepressant’ term in both hippocampal
and cortical datasets. We also noted a strong geneset correlation to
the term ‘anti-inflammatory’, a function previously associated with
AMI [19]. Sixteen and seventeen AMI-regulated genes implicitly
correlated with neurogenesis in the hippocampus and cortex
respectively (Figure 4H). Despite a similar number of AMI-
regulated neurogenesis-associated genes in each tissue, the
accumulated LSI correlation score for all these genes was greater
for the hippocampal (3.45) compared to the cortical set (2.56).
These unbiased bioinformatic data analyses suggested that AMI
could be exerting neurotrophic actions in the aged 36TgAD mice,
which we subsequently investigated.
AMI promotes in vitro neuronal development and
hippocampal adult neurogenesis
We next directly assessed, in vitro and in vivo, the potential
structural neurotrophic actions of AMI. Application (72 hrs) of the
Akt-1/Trk-stimulating AMI doses (10 nM) to primary mouse
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and axonal growth, compared to vehicle-treated cells (Figure 5A).
To assess in vivo neurotrophic actions of AMI, bromo-deoxyuridine
(BrdU) or a vehicle control was administered intraperitoneally to
36TgAD mice (control and AMI-treated), daily for 9 days. BrdU
stably incorporates itself into DNA of newly dividing cells, acting
as a marker of new cell development. 36TgAD mice can display
adult neurogenic behavior, but typically newly developed cells
undergo apoptosis and are unable to develop into mature neurons.
To ensure that any novel AMI-generated BrdU-positive cells were
stable and mature, two months was allowed (with continued
maintenance of vehicle or AMI application) to pass from initial
BrdU injection to the time of tissue harvest. One of the primary
CNS regions of adult neurogenesis is the hippocampus, with the
dentate gyrus (DG) being one of the most important sub-regions.
AMI treatment profoundly increased the number of BrdU positive
cells in the DG, compared to vehicle-treated animals (Figure 5B).
Additional hippocampal sub-regions, i.e. CA1-CA3 demonstrated
only minimal levels of AMI-mediated neurogenesis compared to
the DG (data not shown). Nearly all of the BrdU positive cells were
co-immunoreactive to NeuN staining, indicating their mature
neuronal status. Vehicle-treated animals presented no BrdU
positive cells in any of the hippocampal regions. We also detected
AMI-mediated elevation of expression of multiple hippocampal/
cortical proteins associated with neurogenesis and neuronal
growth/development [20–23], many of which we also identified
using our transcriptomic analysis. AMI induced a consistent
potentiation of Ndrg4 (Figure 5C), flotillin-2 (Flot2: Figure 5D),
glucocorticoid receptor DNA binding factor 1 (Grlf1: Figure 5E)
and neogenin-1 (Neo1: Figure 5F) hippocampal protein expression.
AMI also potentiated cortical expression of Ndrg4 (Figure 5G),
reticulon-4 (Rtn4: Figure 5H) and embryonic lethal abnormal
vision drosophila homolog-like 2 (Elavl2: Figure 5I). It appears
therefore that AMI treatment was able to induce the creation of a
stable cohort of new neurons in the symptomatic, aged 36TgAD
mice. We therefore next investigated whether AMI was able to
directly control the development of cells to a neuronal lineage in
an in vitro environment. To assess the neuronal developmental
capacity of AMI treatment, either AMI or BDNF was applied to
isolated murine neural progenitor (NP) cells for two weeks. AMI-
treatment was able to significantly reduce expression of Sox2
(sex determining region Y-box 2), a marker of undifferentiated
progenitors (Figure 5J), while simultaneously increasing the
expression of mature neurosynaptic markers synapsin I
(Figure 5K) and synaptophysin (Figure 5L). The effects of AMI
closely mirrored those of BDNF upon the NP cells (Figure 5J–L)
with respect to Sox2, synapsin I and synaptophysin expression,
indicating a strong developmental-neurotrophic functionality to
AMI activity.
Discussion
We have shown that AMI treatment in aged and cognitively-
impaired 36TgAD mice resulted in increases of potentially ‘non-
toxic’ Ab plaque load in both the hippocampus (Figure 1A) and
the frontal cortex (Figure 1E), as well as increases in the
hippocampal PHF load in 36TgAD mice (Figure 1F). Despite
the seemingly increased classical AD pathology, AMI-treated
36TgAD mice showed significant increases in neurosynaptic
protein expression and neurotrophin receptor/pro-survival
kinase activity, enhancement of spatial learning and memory
as well as adult hippocampal neurogenesis (Figures 2,3,5).
Increased Ab aggregation was not associated with increases in
b-o rc-secretase enzyme activity (Figure S1). A possible
explanation for this altered amyloid deposition may be linked
to zinc-modulating factors such as the zinc transporter, Slc30a5.
This transcript was elevated by AMI-treatment in both the
hippocampus and cortex (Figure 4B). Slc30a5,a l s ok n o w na s
ZNT5, is associated with neuronal response mechanisms to
elevated amyloid plaque load in AD [24]. ZNT5 expression is
associated with Ab plaques and facilitates translocation of
cytoplasmic zinc ions into the Golgi apparatus [25]. ZNT5
may therefore participate in the AMI response (i.e. elevated
plaque load) process in the 36TgAD mice, by transporting
cytoplasmic zinc ions into the Golgi apparatus and incorporating
them into newly synthesized metalloproteins. The large Ab
histological plaques seen with AMI treatment may also be part of
the therapeutic cognitive effects observed. Large insoluble
plaques have been shown to be unreactive and relatively
harmless to normal cell functioning [26]. The large Ab plaques
induced by AMI-treatment may also act as molecular sinks for
any soluble dimeric Ab. The majority of the Ab in AMI-treated
mice, in both hippocampal cytosolic and insoluble fractions,
consisted of non-toxic monomer and very little toxic dimer
(Figure 1G). Control (vehicle-treated) 36TgAD animals however
contained mainly toxic dimeric Ab and little monomer. Ab
oligomers are considered highly cytotoxic, with dimers being the
smallest form of toxic oligomers [26,27]. The oligomeric
assemblies of Ab transiently arising in the path of fibrillization
of several peptides and proteins associated with amyloid disease
are typically seen as the primary or even sole cytotoxic species of
amyloid [28–32]. Evidence also indicates that intermediate
amyloid oligomer assemblies demonstrate a broad spectrum of
abilities to impair cell physiology and viability, for example, AD-
related neuroinflammation is more specifically associated to the
presence of larger fibrillar Ab [33], whereas smaller Ab
oligomers impair neuronal long-term potentiation [28], raise
endoplasmic reticulum stress [34] and induce cell death following
an aggregation state-specific uptake [35]. It is clear that there is
an intricate and complex relationship between Ab structure and
neurophysiological outcomes. Hence, monomers of Ab may even
be neurotrophic and beneficial for neuronal survival [36]. The
AMI-increased Ab monomer levels could therefore constitute
part of the observed DG neurogenesis (Figure 5B). In addition to
AMI-mediated changes in Ab, the increased PHF load seen with
AMI may also contribute to its therapeutic action. Large
insoluble PHFs, like large Ab plaques, may also be unreactive
and relatively benign, whereas soluble PHFs cause cellular
Figure 4. Hippocampal and cortical AMI genotropic actions. (A) Venn analysis of AMI-significantly-regulated transcripts in 36TgAD cortex (c)
and hippocampus (h) (red-upregulation: green-downregulation; blue-diverse regulation). (B) Commonly AMI-regulated genes and z-ratios (cortex-
black: hippocampus-white). KEGG signaling pathway population, quantified as a ‘hybrid’ score (see Methods) by hippocampus (C) and cortex (D) AMI-
regulated genes. (E) MSigDB PAGE collection population, quantified as aggregate z-score, by significant AMI-regulated hippocampal (E) or cortical (F)
genesets (PAGE collections directly associated with AD-highlighted in red). Percentage gene population of PAGE collection by the input AMI-
regulated geneset is indicated for each red histogram bar. (G) Latent semantic indexing (LSI) GeneIndexer term interrogation of significantly AMI-
regulated hippocampal or cortical genes. Numbers of AMI-regulated genes implicitly correlating with the specific interrogation term are depicted by
the size of the colored bars (red-upregulated: green-downregulated). Total LSI correlation score of all identified genes is indicated above each
histogram bar. (H) Dendrogram association of AMI-regulated hippocampal/cortical neurogenesis-associated genes.
doi:10.1371/journal.pone.0021660.g004
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21660Figure 5. AMI activates neuronal developmental processes. (A) AMI (10 nM, 72 hrs) effect upon primary hippocampal (veh-treated, 1: AMI-
treated, 2) and cortical (veh-treated, 3: AMI-treated, 4) cell morphology, indicated with anti-MAP2 immunoreactivity. (B) AMI/veh effects upon adult
neurogenesis in hippocampal DG (veh: NeuN-1, BrdU-2, overlay-3; AMI: NeuN-4, BrdU-5, overlay-6). AMI-mediated alterations of hippocampal Ndrg4
(C), Flot2 (D), Grlf1 (E) and Neo1 (F) expression. AMI-mediated alterations of cortical Ndrg4 (G), Rtn4 (H) and Elavl2 (I) expression. Western band
intensities were quantified as actin-normalized arbitrary absorbance units (AU:n=3 individual experiments per protein assessed). Two week
treatment of murine neural progenitor cells with AMI (10–20 nM: grey bars) or BDNF (10 ng/mL: white bars) affects Sox2 (J), synapsin I (K) and
synaptophysin (L) expression, compared to vehicle treated (black bars) cells. The associated histograms depict the mean 6 SEM western band
intensity (normalized AU) data from three independent experiments.
doi:10.1371/journal.pone.0021660.g005
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soluble and phosphorylated tau compared to the control group
(Figure 1I, J). In accordance with these potentially therapeutic
effects of AMI upon neurophysiology, AMI also elevated in vivo
hippocampal TrkB tyrosine phosphorylation and downstream
Akt-1 activation levels (Figure 2 O,P). Direct application of AMI
to primary hippocampal cells recapitulated this effect, suggesting
that AMI may directly activate the TrkB receptor. Recent
reports have also suggested that AMI may possess a direct
neurotrophin-like action, independent of the cognate ligands for
Trk family receptors [6]. We also found that AMI also
potentiated hippocampal BDNF tissue levels, suggesting a
potential ‘rejuvenation’ of the 36TgAD hippocampus, as
reductions in BDNF have been associated with increasing age
[37]. Supporting this posit is our demonstration of AMI-
mediated stable DG neurogenesis (Figure 5B) and the in vitro
ability of AMI to induce NP cell development into neuronal
tissue (Figure 5I–K). It is possible that these new hippocampal
DG neurons generated by AMI treatment of the 36TgAD mice
could assist in the creation of new neural networks that facilitate
the pro-cognitive effects seen in our behavioral tests (Figure 3).
Investigation of the alterations in neurite architecture and
dendritic spine density may reveal the relative importance of
such a process in the future. Newly developed cells may also be
more effective at releasing neurotrophic factors, such as BDNF.
Reinforcing an AMI neurotrophic action, we found that AMI
elevated Ndrg4 expression in both the hippocampus and cortex
(Figures 4B, 5C,G). Ndrg4 was primarily identified as a gene
controlling brain development [38] and has recently been shown
to promote neuronal survival, positively regulate neurite
outgrowth as well as regulate neurotrophin receptor signaling
[20]. AMI also increased Anxa3 expression in both the
hippocampus and cortex (Figure 4B) which has been linked to
beneficial neurophysiological changes, including neuronal re-
modeling and development, as well as neurotrophic responses to
voluntary exercise [39]. Voluntary exercise has been demon-
strated to exert beneficial neurological actions via increases in
BDNF levels [40]. We identified several other transcriptomic
changes that may be associated with AMI-mediated neuronal
development, e.g. upregulation of non-imprinted gene in Prader-
Willi Syndrome/Angelman syndrome 1 (Nipa1), Ena-vasodilator
stimulated phosphoprotein (Evl) and sprouty protein with EVH-1
domain 1 (Spred1) [41–43]. With neurogenesis, increased
metabolic support is required and we noted AMI-mediated
regulation of transcripts controlling angiogenesis (brain-specific
angiogenesis inhibitor 2, Bai2; receptor activity modifying
protein 2, Ramp2), stress response (glutaredoxin 2, Glrx2;
oxidation resistance 1, Oxr1) and energy regulation (peroxisome
proliferative activated receptor gamma coactivator 1 beta,
Ppargc1b; mitochondrial carrier homolog 2, Mtch2) [44–49].
Based on the data collected in this study, AMI appears to be an
effective pro-cognitive agent in the old and cognitively-impaired
36TgAD mice employed. It is highly likely that the therapeutic
activity of AMI could be complex and mediated by the subtle
modulation of multiple synergistic processes. Thus the therapeutic
effect of AMI in aged 36TgAD mice is likely to involve multiple
systems including, alterations in amyloid processing, neurotrophin
receptor modulation, neurogenesis, stress resistance and even anti-
inflammatory actions. As AMI has demonstrated a significant
beneficial action in the AD model used in this study the future re-
assessment of well-tolerated, FDA-approved pharmacological
agents, such as AMI, may yield novel, unexpected activities in
different disease states. The divergence in cellular systems and
pharmacological responses between ‘normal’ or ‘diseased’ states
[10,50] therefore may create pathology-specific drug effects that
could usher in new waves of drug development based on studying
approved drugs in novel situations.
Supporting Information
Figure S1 Assessment of beta and gamma secretase
activity in 36TgAD animals. Effects of AMI treatment,
compared to vehicle treatment, upon hippocampal or cortical
beta- or gamma-secretase activity. Beta and gamma secretase
activity is expressed as EDANS (5-((2-aminoethyl)amino)naphtha-
lene-1-sulfonic acid) fluorescence per mg of specific tissue protein.
Secretase activity in vehicle-treated 36TgAD animals is indicated
by black bars while secretase activity in AMI-treated 36TgAD
animals is indicated by grey bars. Hippocampal beta-secretase (A)
and gamma-secretase (B) activity in vehicle- and AMI-treated
36TgAD mice. Cortical beta-secretase (C) and gamma-secretase
(D) activity in vehicle- AMI-treated 36TgAD mice. Values in
histograms represent mean 6 SEM (n=3).
(TIF)
Figure S2 AMI-mediated alteration of synaptic factors
and neuroprotective signaling in extended-culture pri-
mary hippocampal and cortical cells. Murine hippocampal
or cortical primary neurons were extracted as described in the
Methods section. Cells were then allowed to mature for 21 days in
culture before either, 3 additional days of culture with maintained
10 nM AMI stimulation (for PSD95 or synapsin I assessment) or
acute stimulation with the same AMI dose for 20 minutes (for
TrkB tyrosine phosphorylation and Akt-1 Ser-473 phosphoryla-
tion measurement). Representative western blots are represented
with an associated histogram indicating quantifications of the
western blot band intensities expressed as actin-normalized
arbitrary absorbance units (AU). Values in each histogram
represent mean 6 SEM (n=3). AMI effects on synapsin I (A)
and PSD95 (B) expression in primary hippocampal cells after 21
days in culture. AMI effects on synapsin I (C) and PSD95 (D)
expression in primary cortical cells after 21 days in culture. Acute
AMI effects upon TrkB tyrosine phosphorylation (E) and Akt-1
Ser-473 phosphorylation (F) in hippocampal cells after 21 days in
culture. Acute AMI effects upon TrkB tyrosine phosphorylation
(G) and Akt-1 Ser-473 phosphorylation (H) in hippocampal cells
after 21 days in culture.
(TIF)
Table S1 Antisera employed for immunohistochemistry
or western blot analysis. For each antisera used the protein
target, experimental dilution used and the proprietary source (with
catalog number) is delineated.
(DOC)
Table S2 AMI-mediated significant transcriptional al-
terations in adult 36TgAD mouse hippocampus. Z ratios
of genes significantly up- (positive) or down-regulated (negative) in
the hippocampus of 36TgAD mice after AMI treatment
compared to control vehicle treatment (AMI vs. vehicle (veh) z
ratio).
(DOC)
Table S3 AMI-mediated significant transcriptional al-
terations in adult 36TgAD mouse cortex. Z ratios of genes
significantly up- (positive) or down-regulated (negative) in the
cortex of 36TgAD mice after AMI treatment compared to control
vehicle treatment (AMI vs. vehicle (veh) z ratio).
(DOC)
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